SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.43
+3.04 (+5.59%)
At close: 4:00PM EST

57.43 0.00 (0.00%)
After hours: 6:48PM EST

Stock chart is not supported by your current browser
Previous Close54.39
Open54.63
Bid53.00 x 800
Ask57.43 x 800
Day's Range54.05 - 58.50
52 Week Range47.75 - 84.37
Volume3,234,270
Avg. Volume983,510
Market Cap9.197B
Beta (3Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch8 hours ago

    Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment

    Shares of Seattle Genetics Inc. rose more than 6% Friday, after the company said it had received a new approval for its Adcetris therapy as a treatment for previously untreated peripheral T-Cell Lymphoma. The U.S. Food and Drug Administration approved Adcetris in combination with CHP chemotherapy based on the successful outcome of its phase 3 ECHELON-2 clinical trial, the company said in a statement. The FDA used a new approval pathway that allowed it to come just two weeks after the company submitted data and just under two months since it announced topline data. "While this approval was widely anticipated given the Overall Survival benefit and positive trial (ECHELON-2), we believe SGEN shares will react favorably given that it suggests PTCL revenues are likely to start in Q4, and also dispels any risk from the upcoming American Society of Hematology (ASH) presentation, especially in regards to the broader, non-ALCL (anaplastic large cell lymphoma ) cohort, which were included in this label," said Leerink analyst Andrew Berens. Leerink was previously expected revenue to start in 2019. It is the sixth FDA-approved indication for Adcetris. Shares have gained 7% in 2018, while the S&P 500 has gained 2%.

  • Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
    Zacks14 hours ago

    Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

    Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of SGEN earnings conference call or presentation 25-Oct-18 8:30pm GMT

    Q3 2018 Seattle Genetics Inc Earnings Call

  • Microsoft and Seattle Genetics buildings are part of a big Bothell sale
    American City Business Journals14 days ago

    Microsoft and Seattle Genetics buildings are part of a big Bothell sale

    The 17-building property is essentially full with medical device manufacturing, aerospace and telecomm companies also operating there.

  • Seattle Genetics: "Now the Hard Work Begins"
    Motley Fool17 days ago

    Seattle Genetics: "Now the Hard Work Begins"

    Front-line Hodgkin lymphoma turns out to be a tough market to crack.

  • Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
    Zacks21 days ago

    Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark

    Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.

  • Here's Why Seattle Genetics Plummeted Today
    Motley Fool21 days ago

    Here's Why Seattle Genetics Plummeted Today

    Third-quarter earnings weren't what investors (or management) were hoping for.

  • Benzinga22 days ago

    The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 26) Endocyte, Inc. (NASDAQ: ECYT ) Imprimis Pharmaceuticals ...

  • Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool22 days ago

    Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript

    SGEN earnings call for the period ending September 30, 2018.

  • Associated Press22 days ago

    Seattle Genetics: 3Q Earnings Snapshot

    The Bothell, Washington-based company said it had a loss of 42 cents per share. Losses, adjusted for investment costs, came to 27 cents per share. The results matched Wall Street expectations. The average ...

  • Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?
    Zacks25 days ago

    Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?

    Seattle Genetics has been struggling lately, but the selling pressure may be coming to an end soon.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • How Acadia Pharmaceuticals Is Positioned Financially
    Market Realistlast month

    How Acadia Pharmaceuticals Is Positioned Financially

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.

  • Analysts Mostly Positive on Acadia Pharmaceuticals
    Market Realistlast month

    Analysts Mostly Positive on Acadia Pharmaceuticals

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • A Financial Overview of Ionis Pharmaceuticals in October
    Market Realistlast month

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.

  • Cara Therapeutics: Performance and Estimates for Q3
    Market Realistlast month

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

  • What Seattle Genetics’ Valuation Trend Indicates
    Market Realistlast month

    What Seattle Genetics’ Valuation Trend Indicates

    In October, of the 13 analysts covering Seattle Genetics (SGEN), eight analysts gave the stock a “buy” or a higher rating, while five analysts gave the stock a “hold” rating. The mean rating for Seattle Genetics stock is 2.15 with a target price of $87.45, which implies an upside potential of 5.7% over Seattle Genetics’ closing price of $82.76 on October 3.

  • Analyzing Seattle Genetics’ Key Collaborations
    Market Realistlast month

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.

  • Seattle Genetics: Impact of the Cascadian Acquisition
    Market Realistlast month

    Seattle Genetics: Impact of the Cascadian Acquisition

    Seattle Genetics’ (SGEN) net investment and other income increased from $2.91 million in the second quarter of 2017 to $106.56 million in the second quarter of 2018 due to net gains from its sale of Immunomedics common shares. As a result, the company posted a net income of $76.27 million in the second quarter—compared to a net loss of $56.36 million in the second quarter of 2017.

  • What’s Driving Seattle Genetics Stock in 2018?
    Market Realistlast month

    What’s Driving Seattle Genetics Stock in 2018?

    Seattle Genetics’ (SGEN) antibody-drug conjugate technology makes use of monoclonal antibodies’ targeting ability to deliver cell-killing agents to cancer cells. Adcetris, Seattle Genetics’ product on the market, is used to treat several types of lymphoma. The company also has a product pipeline targeted for solid tumors and blood-related cancers.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realistlast month

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • Why Analysts See a Massive Upside in Madrigal Stock
    Market Realistlast month

    Why Analysts See a Massive Upside in Madrigal Stock

    In October, of the nine analysts covering Madrigal Pharmaceuticals (MDGL), six have given its stock “buy” or higher ratings, and three have given it “hold” ratings. The mean rating for Madrigal stock is 2.11, and its target price is $322.86, implying an upside potential of 53.7% over its closing price of $210.08 on October 2. In comparison, peers Endocyte (ECYT) and Seattle Genetics (SGEN) have mean ratings of 1.25 and 2.15, respectively, and target prices of $23.33 and $86.09, respectively.

  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist2 months ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.